{"classes":[{"categories":[{"measurements":[{"comment":"Median TTD and Upper Limit for the 95% confidence interval were not estimated due to the small number of participants with events at data cut off.","groupId":"OG000","lowerLimit":"30.4","upperLimit":"NA","value":"NA"},{"comment":"Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG001","lowerLimit":"21.3","upperLimit":"NA","value":"24.7"}]}],"title":"Median TTD for Coughing Subscale (months)"},{"categories":[{"measurements":[{"comment":"Median TTD, Lower Limit and Upper Limit for the 95% confidence interval were not estimated due to the small number of participants with events at data cut off.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median TTD, Lower Limit and Upper Limit for the 95% confidence interval were not estimated due to the small number of participants with events at data cut off.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Median TTD for Haemoptysis Subscale (months)"},{"categories":[{"measurements":[{"comment":"Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG000","lowerLimit":"20.8","upperLimit":"NA","value":"25.6"},{"comment":"Median TTD and Upper Limit for the 95% confidence interval were not estimated due to the small number of participants with events at data cut off.","groupId":"OG001","lowerLimit":"23.4","upperLimit":"NA","value":"NA"}]}],"title":"Median TTD for Dysphagia Subscale (months)"},{"categories":[{"measurements":[{"comment":"Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG000","lowerLimit":"20.2","upperLimit":"NA","value":"25.2"},{"comment":"Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG001","lowerLimit":"18.2","upperLimit":"NA","value":"23.8"}]}],"title":"Median TTD for Pain in arm or shoulder Subscale (months)"},{"categories":[{"measurements":[{"comment":"Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG000","lowerLimit":"15.7","upperLimit":"NA","value":"23.0"},{"comment":"Upper Limit for the 95% confidence interval (CI) could not be estimated because the follow-up time was too short to observe enough survival events for complete data estimation.","groupId":"OG001","lowerLimit":"18.2","upperLimit":"NA","value":"21.3"}]}],"title":"Median TTD for Pain in other parts Subscale (months)"},{"categories":[{"measurements":[{"comment":"Median TTD and Upper Limit for the 95% confidence interval were not estimated due to the small number of participants with events at data cut off.","groupId":"OG000","lowerLimit":"25.7","upperLimit":"NA","value":"NA"},{"comment":"Median TTD and Upper Limit for the 95% confidence interval were not estimated due to the small number of participants with events at data cut off.","groupId":"OG001","lowerLimit":"25.2","upperLimit":"NA","value":"NA"}]}],"title":"Median TTD for Pain in Chest Subscale (months)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"7.0","value":"4.3"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"9.7","value":"5.8"}]}],"title":"Median TTD for Sore mouth Subscale (months)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"13.1","value":"9.0"},{"groupId":"OG001","lowerLimit":"13.7","upperLimit":"24.6","value":"19.4"}]}],"title":"Median TTD for Dyspnea Subscale (months)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"15.7","value":"11.3"},{"groupId":"OG001","lowerLimit":"9.7","upperLimit":"18.2","value":"15.1"}]}],"title":"Median TTD for Peripheral neuropathy Subscale (months)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"4.3","value":"3.4"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"18.2","value":"8.9"}]}],"title":"Median TTD for Alopecia Subscale (months)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"278"}],"units":"Participants"}],"description":"EORTC QLQ-LC13 has 13 questions and scores range from 0-100 after a linear transformation. Questions assess cough, hemoptysis, dyspnea, site specific pain, sore mouth, dysphagia, peripheral neuropathy, and alopecia and pain medication.\n\nTime to deterioration (TTD) is defined as the time from randomization until the date of the first clinically meaningful worsening (a change in the score from baseline of ≥10) that is confirmed at a subsequent assessment or death in the absence of a clinically meaningful symptom, function, or global health status/QoL worsening, regardless of whether the patient withdraws from study treatment or receives another anticancer therapy prior to symptom, function or GHS/QoL deterioration. The median TTD was calculated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"OG000","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"OG001","title":"Randomized: AZD9291"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set, all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months after the first patient is randomized.","title":"Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items (EORTC QLQ-LC13) (Randomized Component)","type":"SECONDARY","unitOfMeasure":"Months"}